Cargando…
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline–trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 trial (NCT0369...
Autores principales: | Sauder, Colin, Allen, Luke A., Baker, Elizabeth, Miller, Andrew C., Paul, Steven M., Brannan, Stephen K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681874/ https://www.ncbi.nlm.nih.gov/pubmed/36414626 http://dx.doi.org/10.1038/s41398-022-02254-9 |
Ejemplares similares
-
Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022) -
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
por: Kidambi, Neil, et al.
Publicado: (2023) -
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
por: Breier, Alan, et al.
Publicado: (2023) -
Efficacy of trospium for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study
por: Srivastava, Vinit Kumar, et al.
Publicado: (2020) -
Xanomeline restores endogenous nicotinic acetylcholine receptor signaling in mouse prefrontal cortex
por: Power, Saige K., et al.
Publicado: (2023)